1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19484
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSkarlos, D. V.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorAthanassiadis, A.en
dc.contributor.authorStathopoulos, G. P.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorKarphathios, S.en
dc.contributor.authorPapakostas, P.en
dc.contributor.authorBamia, C.en
dc.contributor.authorFountzilas, G.en
dc.date.accessioned2015-11-24T19:00:08Z-
dc.date.available2015-11-24T19:00:08Z-
dc.identifier.issn0093-7754-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19484-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Agents/*administration & dosage/adverse effectsen
dc.subjectAntineoplastic Agents, Phytogenic/*administration & dosage/adverse effectsen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/administration & dosage/adverseen
dc.subjecteffects/*therapeutic useen
dc.subjectArea Under Curveen
dc.subjectCarboplatin/*administration & dosage/adverse effectsen
dc.subjectCause of Deathen
dc.subjectCisplatin/*administration & dosage/adverse effectsen
dc.subjectCombined Modality Therapyen
dc.subjectDisease Progressionen
dc.subjectDrug Administration Scheduleen
dc.subjectFemaleen
dc.subjectFollow-Up Studiesen
dc.subjectGreeceen
dc.subjectHumansen
dc.subjectInfusions, Intravenousen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Stagingen
dc.subjectNeoplasm, Residualen
dc.subjectNeoplasms, Glandular and Epithelial/*drug therapy/pathology/surgeryen
dc.subjectNeutropenia/chemically induceden
dc.subjectOvarian Neoplasms/*drug therapy/pathology/surgeryen
dc.subjectPaclitaxel/*administration & dosage/adverse effectsen
dc.subjectRemission Inductionen
dc.subjectSurvival Rateen
dc.subjectThrombocytopenia/chemically induceden
dc.titlePaclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group studyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/9346224-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1997-
heal.abstractNinety previously untreated patients with advanced epithelial ovarian cancer (International Federation of Gynecology and Obstetrics stages IIC, III, and IV) were randomized, after initial cytoreductive surgery, to receive paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 as a 3-hour infusion with either carboplatin at an area under the concentration-time curve of 7 (group A) or carboplatin at an area under the concentration-time curve of 7 on courses 1, 3, and 5, alternating with cisplatin 75 mg/m2 on courses 2, 4, and 6 (group B). Treatment was given every 3 weeks, up to a total of six courses. Sixty-one patients (33 and 28 patients in groups A and B, respectively) had residual disease after the initial cytoreductive surgery. Patients with measurable or evaluable disease had a high overall response (82% v 57%). A 52% and 39% complete response rate for groups A and B, respectively, with no statistically significant difference between the groups was also observed. With a median follow-up of 12 months (range, 0.33 to 24 months), 29 patients have progressed (18 and 11 in groups A and B, respectively), and 13 have died (seven and six, respectively). Median time to progression was 20.36 months (range, 0.20 to 23.54 months) for group A, whereas this has not yet been reached for group B. Median survival has not yet been reached, but there is no significant difference between the two groups (P = .6972). Treatment was generally well tolerated. Grade 3 and 4 neutropenia was 20% and 32% for groups A and B, respectively, while grade 3 and 4 thrombocytopenia was 4% and 7%, respectively, with no significant difference between the two groups. In conclusion, both combinations seem very active for the treatment of advanced epithelial ovarian cancer and are associated with acceptable toxicity.en
heal.journalNameSemin Oncolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons